RAMOSE Phase II trial finds promising results for osimertinib and ...
2024年12月10日 · 1. Treatment of patients with tyrosine kinase inhibitor (TKI)-naïve epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) with osimertinib and ramucirumab resulted in a significantly longer progression-free survival (PFS) compared with osimertinib alone. Evidence Rating Level: 1 (Excellent) Study Rundown: The current standard of care for patients with advanced EGFR ...
Amivantumab plus lazertinib improves survival in EGFR-mutated …
2024年11月27日 · 1. In this randomized trial, amivantamab-lazertinib led to significantly longer progression-free survival than osimertinib therapy for mutated advanced non-small-cell lung cancer (NSCLC). 2. Amivantamab-lazertinib showed superior efficacy to osimertinib as first-line therapy for epidermal growth factor receptor (EGFR) mutated advanced NSCLC. Evidence Rating Level: 1 (Excellent) Study Rundown ...
Adjuvant durvalumab therapy improves survival in limited-stage …
2024年11月21日 · 1. In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival compared to placebo in patients with limited-stage small cell lung cancer (SCLC). 2. Durvalumab had a tolerable safety profile, with a comparable incidence of adverse effects to the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: Small
Point of care C-reactive protein testing may be useful in guiding ...
2024年12月6日 · 1. C-reactive protein (CRP)-point-of-care tests can be used to guide antibiotic prescribing in primary care for patients with acute exacerbations of COPD with no reduction in patient outcome Evidence Rating Level: 1 (Excellent) About 80% of patients presenting with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) to primary care are often given antibiotics that
Axonal injury may occur up to 9 years prior to symptom onset in ...
2024年12月3日 · 1. Multiple sclerosis patients can sustain axonal injury up to 9 years before symptom onset. 2. Until symptom onset, physical and mental well-being are comparable between affected and unaffected individuals. Evidence Rating Level: 3 (Average) Multiple sclerosis (MS) has an unclear mechanism and onset with physiological changes occurring well …
Glucagon-like peptide-1 receptor agonists may impact outcomes …
2024年10月28日 · 1. The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not associated with increased risks of pulmonary aspiration during upper gastrointestinal endoscopy discontinuation compared to the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors. 2. The use of GLP-1 receptor agonists among adults with T2DM was associated
Early oral anticoagulation is non-inferior to delayed treatment in ...
2024年12月11日 · 1. Early DOAC therapy within 4 days was non-inferior to delayed therapy for the composite outcome of recurrent ischemic or unclassified stroke, symptomatic intracranial hemorrhage, and systemic embolism at 90 days. Evidence Rating Level: 1 (Excellent) Study Rundown: The optimal timing for starting anticoagulation in patients with acute ischemic stroke and atrial fibrillation remains unclear,
Influenza vaccination may reduce secondary infection spread …
2024年12月1日 · 1. Influenza vaccination was associated with a reduced risk of secondary influenza infections among household contacts, with an estimated effectiveness of 21%. Evidence Rating Level: 2 (Good) Influenza vaccinations are recommended for all individuals aged 6 months and older in the United States for the prevention of influenza infection. However, while the effectiveness of influenza
Multi-component sleep-mood group interventions may improve …
2024年11月14日 · 1. In this pilot randomized controlled trial, the Sleep Mood Intervention: Life Effectively (SMILE) intervention was associated with improvements in insomnia in university students. Evidence rating level: 1 (Excellent) Insomnia has a major burden on public health and can have serious long-term physical and mental health effects if left untreated.
Landmark Trials & Summaries: The Classics in Medicine - 2 Minute …
Title Year Journal Citations Key findings; The UKPDS: Reducing the risk of diabetes-related morbidity and mortality: 1998: Lancet: 20,000: 1. For patients with type 2 diabetes mellitus, pharmacologic blood glucose control with sulfonylureas or insulin significantly reduces the risk of microvascular complications, but not macrovascular complications